Akari Therapeutics (NASDAQ:AKTX) Receives New Coverage from Analysts at B. Riley

Retrieved on: 2018-03-04 10:02:57

Tags for this article:

Short

Financial regulation

Celsus Therapeutics Plc

Akari Therapeutics Plc

Click the tags to see associated articles and topics

Akari Therapeutics (NASDAQ:AKTX) Receives New Coverage from Analysts at B. Riley. View article details on hiswai:

Excerpt

<div><b>Millennium Management</b> LLC raised its holdings in shares of Akari Therapeutics by 125.0% during the fourth quarter. <b>Millennium Management</b> LLC now owns 260,020 shares of the biopharmaceutical company's stock valued at $1,126,000 after acquiring an additional 144,477 shares during the period.</div>

Article found on:

View Original Article